Skip to main
SXTP

SXTP Stock Forecast & Price Target

SXTP Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

60 Degrees is looking to expand in the infectious disease market with its unique pipeline of therapies aimed at vector-borne, fungal, and viral diseases, which have limited treatment options currently available. Its successful commercial efforts have led to steady growth in its product revenues, which is expected to increase further with initiatives to increase awareness and market access for its lead asset, Arakoda, used in preventing certain types of malaria. Despite recent financing activities and a reverse stock split, analysts remain bullish on the company's prospects, citing its potential for further partnerships and approvals in additional indications. Risks include clinical trial outcomes and potential dilution from future financings.

Bears say

60 Degrees is facing a setback to revenue growth with its market access partnership with Runway Health - a new pillar to the company's ARKODA marketing strategy - being delayed until April 2026. While the company has broadened its pipeline with the submission of a notification to the FDA for Australian Chestnut Extract, there is a risk of gross margins being negatively impacted in the short-term due to a one-time inventory write-off. However, the company is confident in the potential of its product for babesiosis, reaffirming its blockbuster potential and securing a strong position in the TAM market.

SXTP has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of 60 Degrees Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 60 Degrees Pharmaceuticals Inc (SXTP) Forecast

Analysts have given SXTP a Strong Buy based on their latest research and market trends.

According to 2 analysts, SXTP has a Strong Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

60 Degrees Pharmaceuticals Inc (SXTP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.